AngioDynamics (NASDAQ:ANGO) Stock Falls 7.1% – Should You Sell?

AngioDynamics, Inc. (NASDAQ:ANGO)’s share price was down 7.1% during mid-day trading on Tuesday. The stock traded as low as $14.51 and last traded at $14.4350. 272,285 shares changed hands during mid-day trading, a decline of 43% from the average daily volume of 478,868 shares. The stock had previously closed at $15.54.

Key Stories Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported fiscal Q1 2027 revenue of approximately $80.9 million, up 6.9% year over year, while its adjusted loss of $0.04 per share was better than the consensus loss estimate of $0.11. Gross margin also improved to 59.4% from 55.3%. AngioDynamics Fiscal Q1 2027 Financial Results
• Positive Sentiment: Growth was strongest in key products: Auryon sales increased 14.7% to $18.9 million, while NanoKnife sales rose 29.0% to $8.3 million. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia, potentially expanding the technology’s addressable market. AngioDynamics Sales and Product Update
• Neutral Sentiment: Management reaffirmed fiscal 2027 revenue guidance of $336 million to $341 million and EPS guidance of a $0.24 to $0.29 loss. The revenue range is broadly in line with analyst expectations, but it does not signal a major acceleration. AngioDynamics Fiscal 2027 Guidance
• Negative Sentiment: Despite the adjusted EPS beat, AngioDynamics remains unprofitable. Reported GAAP net loss was $7.1 million, or $0.17 per share, and operating cash flow was negative $15.3 million, with $34.0 million in cash at quarter-end. AngioDynamics Q1 Loss Report
• Negative Sentiment: The company is entering a leadership transition: Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The change may add uncertainty while investors are already scrutinizing profitability and cash consumption. AngioDynamics CEO Appointment

Analyst Ratings Changes

Several analysts have issued reports on the stock. Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. HC Wainwright upped their price objective on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, Canaccord Genuity Group increased their target price on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, AngioDynamics currently has an average rating of “Moderate Buy” and a consensus target price of $19.50.

AngioDynamics Trading Down 19.1%

The business has a 50-day moving average price of $15.46 and a 200-day moving average price of $13.11. The firm has a market cap of $482.65 million, a P/E ratio of -13.18 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $80.92 million for the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, equities analysts anticipate that AngioDynamics, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

A number of institutional investors have recently added to or reduced their stakes in ANGO. BlackRock Inc. bought a new stake in shares of AngioDynamics in the 2nd quarter valued at about $49,480,000. Armistice Capital LLC grew its holdings in AngioDynamics by 3.9% in the fourth quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after purchasing an additional 64,000 shares during the last quarter. Weber Capital Management LLC ADV purchased a new position in AngioDynamics in the second quarter worth $17,649,392. Bastion Asset Management Inc. boosted its position in shares of AngioDynamics by 17.4% in the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock worth $14,107,000 after purchasing an additional 194,822 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in AngioDynamics by 3.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock worth $10,786,000 after buying an additional 32,476 shares during the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.